in

Belgian clinical-stage biopharmaceutical company: Celyad SA (CYAD) (2007)

CELYAD SA (NASDAQ) was established in 2004, formerly known as Cardio3 BioSciences SA, and changed to its current name in May 2015. It is headquartered in Mont-Saint-Guibert, Belgium and has 80 full-time employees (12/31/2018). Clinical stage biopharmaceutical company, focusing on the development of CAR-T cell therapy.

Celyad SA

Celyad SA (CYAD):

Celyad uses its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treat a series of solid and hematological tumors.

At present, Celyad’s main drug candidate product is only one-CYAD-01 (CAR-T NKG2D) has been evaluated in a phase I clinical trial to evaluate the effectiveness of multiple autologous CYAD-01 cells in 7 refractory cancers. Safety and clinical activity, including 5 solid tumors, such as colorectal cancer, ovarian cancer, bladder cancer, triple negative breast cancer and pancreatic cancer; 2 hematological tumors including acute myeloid leukemia and multiple myeloma.

Celyad SA (CYAD) investment:

Celyad is a company listed on Euronext in Brussels and Euronext in Paris. It submitted the Nasdaq IPO prospectus to the SEC on 5/18/2015 and landed on the US capital market on June 19, 2015. The issue price $ 68.56 , financing of 115 million US dollars, stock code: CYAD.

CYAD broke -20.41% on the first day of listing and closed at $54.57.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

The world’s largest tissue manufacturer: Kimberly-Clark Corporation (KMB) (1872)

Transportation expert: Ryder System(R) (1933)